Skip to main content
TipRanks
Go Ultimate75% OFF

Paxman AB (PXMBF) Q2 2026 Earnings Report

4 Followers

PXMBF Q2 2026 EPS Results

Actual EPS
$0.01
Consensus EPS
$0.03
Beat/Miss
Missed by -$0.02
One Year Ago EPS
-$0.01

PXMBF Q2 2026 Revenue Results

Actual Revenue
$10.29M
Expected Revenue
$9.36M
Beat/Miss
Beat by +$935.83K
YoY Revenue Growth
+40.26%

Earnings Announcement Details

Quarter
Q2 2026
Date
08/21/2026
Time
Before Open
Conference Call
Friday, August 21, 2026
PXMBF Upcoming Earnings

Paxman AB's next earnings date is estimated for February 19, 2027, based on past reporting schedules.

Q2 2026 Earnings Call Audio

PXMBF Q2 2026 Earnings Call
0:00 / 0:00

Q2 2026 Earnings Slide Deck

No slide deck is available for this earnings event.

Q2 2026 Earnings Call Summary

Q2 2026
Earnings Call Date:Aug 21, 2026|% Change Since:0.00%|
Earnings Call Sentiment|Positive

The call highlights strong commercial momentum: record quarterly sales (+40% YoY), substantial U.S. revenue growth (~+77.5% YoY), large increases in insurance-based billing (110%), improved adjusted margins (~19%), a robust order book (190 systems, 80 in U.S.), and a healthy cash position (SEK 105m). These positives are tempered by a regulatory setback for the neuropathy device (shift to De Novo with an 8–12 month review window), increased operating and CIPN-related costs (OpEx up ~SEK 6m q/q; CIPN costs up ~30%), and a slower near-term U.S. rollout for CIPN. Overall, company fundamentals and commercial traction are strong and appear to outweigh the regulatory and cost challenges, but the De Novo timeline introduces meaningful near-term uncertainty for the new product launch.

Company Guidance

Guidance from the call (Q2 FY2026) flagged concrete near‑term targets and key metrics: group sales were just over SEK 105m (≈40% YoY growth) with EBITDA around SEK 14m (Dignitana contributing ~SEK 5.2m), adjusted EBITDA margin ~18.5% (13% including CIPN costs), cash ≈SEK 105m on the balance sheet and ~SEK 5m movement in available cash. Operational datapoints: 56 systems delivered in Q2, 1,326 caps sold via insurance‑based billing (IBBM) as IBBM revenue grew ~110%, order book at 190 systems (80 in the U.S.), and utilization markedly higher under IBBM (8.6 patients/site, 3.4 patients/system) vs self‑pay (3.1/site, 1.6/system). CIPN program: De Novo submission planned this month with an FDA review horizon of ~150 days (overall 8–12 months expected) targeting U.S. commercialization in Q2 2027; build plan includes 50 units already deployed for pilots and up to 150 units with V2 commercial units to start production in Q4 (Oct–Dec). Costs and working capital: OpEx rose ~SEK 6m Q1→Q2 with CIPN/other costs ~SEK 5.6m this quarter (vs SEK 4.3m prior), and management reiterated Europe roll‑out plans (Sept in DE/FR/ES/NL) and a CapEx+consumables commercial model for neuropathy.

  • Record Group Sales and Strong YoY GrowthGroup sales totaled just over SEK 105 million, the first time exceeding SEK 100 million, representing approximately 40% year-on-year growth.
  • Improved Profitability and EBITDA Contribution from AcquisitionQuarterly EBITDA was about SEK 14 million; the Dignitana acquisition contributed roughly SEK 5.2 million to EBITDA. Adjusted EBITDA margin was nearly 19% (18.5% reported), showing margin improvement year-over-year.
  • Significant Insurance-Based Billing (IBBM) ExpansionInsurance-based billing revenues grew 110%, driving utilization and recurring revenue via caps (1,326 caps sold through IBBM this quarter).
  • Strong U.S. Revenue MomentumU.S. revenues for the group reached $7.1 million this quarter versus $4.0 million in the same quarter 2025, approximately +77.5% year-on-year growth.
  • Robust Order Book and Installations56 systems were delivered in the quarter. Order book stands at 190 systems on order, with 80 of those in the U.S., indicating continued demand and future revenue potential.
  • Material Utilization Uplift Under IBBMUtilization under IBBM materially exceeds self-pay: self-pay averages 3.1 patients per site (1.6 per system) versus IBBM averages of 8.6 patients per site (3.4 per system), demonstrating the revenue leverage from switching to IBBM.
  • Solid Cash PositionAvailable cash remains strong with SEK 105 million in the bank, and management notes a generally positive cash flow trend despite investments.
  • Integration and Stabilization of DignitanaPost-acquisition stabilization underway with cross-company synergies, US activity investments and positive early momentum on utilization and IBBM adoption in Dignitana markets.

PXMBF Earnings History

PXMBF earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Feb 19, 20272026 (Q4)―--0.04――
Nov 20, 20262026 (Q3)0.04-0.01―
Aug 21, 20262026 (Q2)0.030.01-0.01200.00% (+0.02)
May 21, 20262026 (Q1)0.010.00-0.03100.00% (+0.03)
Feb 27, 20262025 (Q4)0.00-0.040.06-166.67% (-0.10)
Nov 14, 20252025 (Q3)0.000.010.02-50.00% (-0.01)
Aug 20, 20252025 (Q2)0.01-0.010.05-120.00% (-0.06)
May 16, 20252025 (Q1)―-0.030.07-142.86% (-0.10)
Feb 21, 20252024 (Q4)0.060.06-0.01700.00% (+0.07)
Nov 15, 20242024 (Q3)0.060.020.04-50.00% (-0.02)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed